R5 collaborates with Emultech
Partnership will provide a unified platform for expansion
Formulation development specialist R5, acquired last year by UK contract pharmaceutical services provider Aesica, is to collaborate with EmulTech, a Dutch specialist contract development organisation focused on drug delivery systems.
As both businesses operate in niche formulation development fields, R5 said the strategic partnership would provide a unified platform from which they can expand more rapidly, while enhancing their bespoke service provision.
R5 develops new medicines and clinical trial materials and provides pharmaceutical dosage form development across Europe.
EmulTech’s drug delivery systems use the firm’s proprietary emulsion technology for micro encapsulates (ET4ME), which enables it to test various formulations, requiring only small volumes.
R5 said the collaboration would enhance productivity, provide increased value to clients and enable shorter development times.
Paul Titley, md of R5 Formulation Development, said: ‘Working with EmulTech will further enhance our credibility and we hope to create a long-term strategic partnership that enables us to innovate within the formulation development arena and consolidate our respective businesses.’
Fränk de Jong, chief executive of EmulTech, added: ‘The uniformity and reproducibility of the products that we develop through our process will seamlessly integrate in the cGMP workflow of R5. As a result, our customers will experience increased value, an enhanced service and leaner development times, all of which are essential qualities in the current marketplace.’
